First-line chemotherapy comparison for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epithelial ovarian, fallopian tube, or peritoneal cancer confirmed by pathology and it is stage III–IV
- You feel well enough for treatment (Eastern Cooperative Oncology Group “PS” score 0–2)
- You have not taken part in another drug study in the last 4 weeks
- Your estimated survival is at least 6 months, and scans show measurable disease that can be tracked (RECIST 1.1)
- You can attend clinic visits and blood tests during the study
- You have no certain exclusions like prior pelvic chemotherapy/radiation or major nerve, heart, liver, kidney, or blood problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This Phase 3 trial tests two chemotherapy regimens (TC vs BEP) for women with malignant sex cord-stromal tumors of the ovary. It aims to see which treatment works better after you’ve had initial surgery to diagnose and/or remove tumor.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
Hear when a new Epithelial Ovarian Carcinoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.